Quarterly ResultAug 11, 2026, 09:21 AM
Microbot Medical Q2 Net Loss $(5.6)M; Reports First Revenues
AI Summary
Microbot Medical Inc. reported a net loss of $(5.6) million for the three months ended June 30, 2026, compared to $(3.5) million in the prior year. The company commenced revenue recognition, generating $241 thousand in Q2 2026 and $346 thousand for the six months ended June 30, 2026. As of June 30, 2026, the company held $64.2 million in marketable securities and stated it has sufficient funds for over twelve months of operations, despite increased operating cash burn.
Key Highlights
- Net loss for Q2 2026 increased to $(5.6) million from $(3.5) million in Q2 2025.
- Net loss for the six months ended June 30, 2026, was $(9.3) million, up from $(6.1) million in H1 2025.
- The company commenced revenue recognition, reporting $241 thousand in Q2 2026 and $346 thousand for H1 2026.
- Cash and cash equivalents were $3.15 million, and marketable securities were $64.2 million as of June 30, 2026.
- Net cash used in operating activities for H1 2026 was $(10.0) million, compared to $(5.4) million in H1 2025.
- Total shareholders' equity decreased to $68.9 million as of June 30, 2026, from $77.5 million at year-end 2025.
- Management believes available funds are sufficient to cover operations for more than twelve months.
- The company is monitoring the Middle East conflict, which has not yet materially affected operations.
Price Impact
More from MBOT